Alvotech ALVO

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating income $78.2M$69.6M-$354.9M-$346.4M-$235.5M-$137.5M—
Net income $27.9M-$231.9M-$551.7M-$513.6M-$101.5M-$170.0M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Total assets $1.49B$1.22B$950.1M$828.4M$598.0M——
Total equity -$284.5M-$412.8M-$932.5M-$564.4M-$135.6M-$867.2M-$767.5M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001898416-26-000004.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
  • Income tax
Revenue, Gross profit, Net income, Income tax by fiscal year, in US dollars The same figures are in the table below this chart. -600M -400M -200M 0 200M Net income, FY2020: -170M Net income, FY2021: -101.5M Net income, FY2022: -513.6M Net income, FY2023: -551.7M Net income, FY2024: -231.9M Net income, FY2025: 27.9M FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — — — — — — —
Gross profit — — — — — — —
Net income — -$170.0M -$101.5M -$513.6M -$551.7M -$231.9M $27.9M
Income tax — — — — — — —

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $236.38B 30.7x 10.0%
GILD GILEAD SCIENCES, INC. $187.23B 22.3x 2.4%
MRNA Moderna, Inc. $58.11B — -39.9%
RVMD Revolution Medicines, Inc. $45.01B — —
BIIB BIOGEN INC. $32.60B 25.1x 2.2%
SCNI Scinai Immunotherapeutics Ltd. $25.80B — 99.2%
NBIX NEUROCRINE BIOSCIENCES INC $15.82B 33.3x 21.4%
EXEL EXELIXIS, INC. $14.62B 21.2x 7.0%